Inovio Pharmaceuticals
INO
INO
124 hedge funds and large institutions have $21.6M invested in Inovio Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 23 increasing their positions, 44 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
33% less capital invested
Capital invested by funds: $32.1M → $21.6M (-$10.4M)
48% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 44
Holders
124
Holding in Top 10
–
Calls
$229K
Puts
$17K
Top Buyers
| 1 | +$178K | |
| 2 | +$175K | |
| 3 | +$151K | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$116K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$62.3K |
Top Sellers
| 1 | -$1.15M | |
| 2 | -$1.14M | |
| 3 | -$810K | |
| 4 |
Charles Schwab
San Francisco,
California
|
-$439K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$388K |